Erysipelas epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Luke Rusowicz-Orazem, B.S.

Overview

Epidemiological and demographic information on erysipelas is not fully documented. Research in Belgium in 2004 approximated the incidence of erysipelas to be 249 per 100,000 individuals in Europe. Erysipelas primarily affects individuals older than 50 years, with median ages between 55 and 60 years old. Data are inconclusive with regards to the predominant gender in erysipelas patients; studies have shown both a predominance in males and females in different patient population samples.

Epidemiology and Demographics

Incidence

Research in Belgium in 2004 approximated the incidence of erysipelas to be 249 per 100,000 individuals in Europe.^[1]

Age

Erysipelas primarily affects individuals older than 50 years of age.

Research from November 1988 – October 1990 in Sweden indicated a median age of 61 years old for erysipelas patients.^[2]
Research in Greece from 1999-2002 indicated a median age of 54.5 years old for erysipelas patients.^[3]
Research in Hungary from 2001-2002 indicated a median age of 59 years old for erysipelas patients.^[4]

Gender

Data are inconclusive with regards to the predominant gender in erysipelas patients.

Studies have shown both a predominance in males and females in different patient population samples.^[4]^[3]^[2]

Race

There is no racial predilection to erysipelas.

Developed and Developing Countries

There is no geographic predilection to erysipelas.

References

↑ Bartholomeeusen S, Vandenbroucke J, Truyers C, Buntinx F (2007). “Epidemiology and comorbidity of erysipelas in primary care”. Dermatology (Basel). 215 (2): 118–22. doi:10.1159/000104262. PMID 17684373.
↑ ^2.0 ^2.1 Eriksson, B.; Jorup-Ronstrom, C.; Karkkonen, K.; Sjoblom, A. C.; Holm, S. E. (1996). “Erysipelas: Clinical and Bacteriologic Spectrum and Serological Aspects”. Clinical Infectious Diseases. 23 (5): 1091–1098. doi:10.1093/clinids/23.5.1091. ISSN 1058-4838.
↑ ^3.0 ^3.1 Krasagakis K, Valachis A, Maniatakis P, Krüger-Krasagakis S, Samonis G, Tosca AD (2010). “Analysis of epidemiology, clinical features and management of erysipelas”. Int. J. Dermatol. 49 (9): 1012–7. PMID 20931671.
↑ ^4.0 ^4.1 Vâţă D, Solovăstru LG, Vâţă A, Dorobăţ C (2011). “[Demographic, clinical and laboratory characteristics of erisypelas in the period 2001-2010]”. Rev Med Chir Soc Med Nat Iasi (in Romanian). 115 (4): 1042–7. PMID 22276443.

Template:WH Template:WS

[pmid17684373-1] Bartholomeeusen S, Vandenbroucke J, Truyers C, Buntinx F (2007). “Epidemiology and comorbidity of erysipelas in primary care”. Dermatology (Basel). 215 (2): 118–22. doi:10.1159/000104262. PMID 17684373.

[ErikssonJorup-Ronstrom1996-2] 2.0 ^2.1 Eriksson, B.; Jorup-Ronstrom, C.; Karkkonen, K.; Sjoblom, A. C.; Holm, S. E. (1996). “Erysipelas: Clinical and Bacteriologic Spectrum and Serological Aspects”. Clinical Infectious Diseases. 23 (5): 1091–1098. doi:10.1093/clinids/23.5.1091. ISSN 1058-4838.

[pmid20931671-3] 3.0 ^3.1 Krasagakis K, Valachis A, Maniatakis P, Krüger-Krasagakis S, Samonis G, Tosca AD (2010). “Analysis of epidemiology, clinical features and management of erysipelas”. Int. J. Dermatol. 49 (9): 1012–7. PMID 20931671.

[pmid22276443-4] 4.0 ^4.1 Vâţă D, Solovăstru LG, Vâţă A, Dorobăţ C (2011). “[Demographic, clinical and laboratory characteristics of erisypelas in the period 2001-2010]”. Rev Med Chir Soc Med Nat Iasi (in Romanian). 115 (4): 1042–7. PMID 22276443.

[1]

[2]

[3]

[4]